---
title: "Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295657353.md"
description: "Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Zevra Therapeutics (ZVRA) with a $20.00 price target, while shares closed at $11.34. Kulkarni holds a 5-star TipRanks rating. The stock enjoys a Strong Buy consensus from analysts, with an average price target of $25.25, implying significant upside. Additionally, Guggenheim maintained a Buy rating with a $23.00 target in early August."
datetime: "2026-08-12T11:27:48.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295657353.md)
  - [en](https://longbridge.com/en/news/295657353.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295657353.md)
---

# Canaccord Genuity Sticks to Its Buy Rating for Zevra Therapeutics (ZVRA)

Canaccord Genuity analyst Sumant Kulkarni reiterated a Buy rating on Zevra Therapeutics yesterday and set a price target of $20.00. The company’s shares closed yesterday at $11.34.

### Claim 55% Off TipRanks

-   Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
-   Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks

According to TipRanks, Kulkarni is a 5-star analyst with an average return of 13.5% and a 50.30% success rate. Kulkarni covers the Healthcare sector, focusing on stocks such as Zevra Therapeutics, Definium Therapeutics, and COMPASS Pathways.

Zevra Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $25.25, representing a 122.66% upside. In a report released on August 6, Guggenheim also maintained a Buy rating on the stock with a $23.00 price target.

### Related Stocks

- [ZVRA.US](https://longbridge.com/en/quote/ZVRA.US.md)
- [DFTX.US](https://longbridge.com/en/quote/DFTX.US.md)
- [CMPS.US](https://longbridge.com/en/quote/CMPS.US.md)

## Related News & Research

- [Zevra: Buy Rating Reaffirmed on Strong MIPLYFFA Momentum and U.S. NPC Opportunity; Price Target Maintained at $35](https://longbridge.com/en/news/295278479.md)
- [Zevra Therapeutics Chief Legal & Compliance Rahsaan Thompson sells 42,666 shares for $474,781.44](https://longbridge.com/en/news/296143510.md)
- [Denison Mines (DNN) Receives a Buy from Roth MKM](https://longbridge.com/en/news/296056406.md)
- [Barclays Keeps Their Buy Rating on RWE AG (0HA0)](https://longbridge.com/en/news/295941081.md)
- [Jefferies Reaffirms Their Hold Rating on Cosan S.A. (CSAN3)](https://longbridge.com/en/news/295881930.md)